Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): A case-case analysis of benzene exposure

Chemico-Biological Interactions

Volumn 184, Issue 1-2, 2010, Pages 30-38

  Irons, Richard D ^a,b,c,d   Gross, Sherilyn A ^a,c   Le, Anh ^c   Wang, Xiao Qin ^a,f   Chen, Yan ^a   Ryder, John ^a,d   Schnatter, A Robert ^e  

^a FUDAN UNIVERSITY   (China)

^b Cinpathogen Inc   (China)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^f FUDAN UNIVERSITY   (China)

Author keywords

Benzene; Cytogenetic abnormalities; Eosinophil dysplasia; Immune mediated; Myelodysplasia

Indexed keywords

BENZENE;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; EOSINOPHIL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OCCUPATIONAL EXPOSURE; QUESTIONNAIRE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK ASSESSMENT; WORK ENVIRONMENT; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; BENZENE; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OCCUPATIONAL EXPOSURE; PREVALENCE; PROSPECTIVE STUDIES; SURVIVAL;

EID: 77950629931     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.11.016     Document Type: Article

References (47)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissue. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue 2008, IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Jaffe E., Harris N., Stein H., Vardiman J. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon, France. E. Jaffe, N. Harris, H. Stein, J. Vardiman (Eds.).
3. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leukemia Research 2000, 24:983-992.
4. Matsuda A., Germing U., Jinnai I., Misumi M., Kuendgen A., Knipp S., Aivado M., Iwanaga M., Miyazaki Y., Tsushima H., Sakai M., Bessho M., Tomonaga M. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005, 106:2633-2640.
5. Kuendgen A., Matsuda A., Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence?. Leukemia Research 2007, 31:103-104.
6. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., Cui J., Chen Z.M., Cao Q., Yang G., Yao Y., Xia H.L., Tong J.H., Li J.M., Chen J., Xiong S.M., Shen Z.X., Waxman S., Chen Z., Chen S.J. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005, 19:767-775.
7. Irons R.D., Wang X., Gross S.A., Bao L., Ryder J., Chen Y., Chen H., Sun H., Zhou J., Ji M., Du X., Fu H., Lin G. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leukemia Research 2006, 30:769-775.
8. Wang X.Q., Ryder J., Gross S.A., Lin G., Irons R.D. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. International Journal of Hematology 2009, 90:361-369.
9. Cuneo A., Fagioli F., Pazzi I., Tallarico A., Previati R., Piva N., Carli G.M., Balboni M., Castoldi G. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. Leukemia Research 1992, 16:789-796.
10. Hayes R.B., Yin S.N., Dosemeci M., Li G.L., Wacholder S., Travis L.B., Li C.Y., Rothman N., Hoover R.N., Linet M.S. Benzene and the dose-related incidence of hematologic neoplasms in China. Journal of the National Cancer Institute 1997, 89:1065-1071.
11. Irons R.D., Lv L., Gross S.A., Ye X., Bao L., Wang X.Q., Ryder J., Armstrong T.W., Zhou Y., Miao L., Le A.T., Kerzic P.J., Ni W., Fu H. Chronic exposure to benzene results in a unique form of dysplasia. Leukemia Research 2005, 29:1371-1380.
12. Armstrong T., Zhou Y., Zhang C., Bowes S., Liang Y., Wong O., Hua F. Exposure assessment for a case-control epidemiology study based in Shanghai, China: summary of methods and results. Chem. Biol. Interact. 2010, 184:286-289.
13. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., Vardiman J.W., Rowley J.D., Larson R.A. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
14. Chen G., Zeng W., Miyazato A., Billings E., Maciejewski J.P., Kajigaya S., Sloand E.M., Young N.S. Distinctive gene expression profiles of Cd34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104:4210-4218.
15. Qian Z., Fernald A.A., Godley L.A., Larson R.A., Le Beau M.M. Expression profiling of Cd34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:14925-14930.
16. Irons R.D., Stillman W.S. The process of leukemogenesis. Environmental Health Perspectives 1996, 104:1239-1246.
17. - bone marrow cells. Experimental Hematology 2000, 28:169-176.
18. Stillman W.S., Varella-Garcia M., Gruntmeir J.J., Irons R.D. The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line. Leukemia 1997, 11:1540-1545.
19. Stillman W.S., Varella-Garcia M., Irons R.D. The benzene metabolites hydroquinone and catechol act in synergy to induce dose-dependent hypoploidy and -5q31 in a human cell line. Leukemia and Lymphoma 1999, 35:269-281.
20. Smith M.T., Zhang L.P., Jeng M., Wang Y.X., Guo W.H., Duramad P., Hubbard A.E., Hofstadler G., Holland N.T. Hydroquinone, a benzene metabolite, increases the level of aneusomy of chromosomes 7 and 8 in human CD34-positive blood progenitor cells. Carcinogenesis 2000, 21:1485-1490.
21. Smith M.T., Zhang L.P., Wang Y.X., Hayes R.B., Li G.L., Wiemels J., Dosemeci M., Titenko-Holland N., Xi L.Q., Kolachana P., Yin S.N., Rothman N. Increased translocations and aneusomy in chromosomes 8 and 21 among workers exposed to benzene. Cancer Research 1998, 58:2176-2181.
22. Ruiz M.A., Augusto L.G., Vassallo J., Vigorito A.C., Lorand-Metze I., Souza C.A. Bone marrow morphology in patients with neutropenia due to chronic exposure to organic solvents (benzene): early lesions. Pathology Research and Practice 1994, 190:151-154.
23. Cazzola M., Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. The New England Journal of Medicine 2005, 352:536-538.
24. Barrett A.J. Myelodysplastic syndrome - an example of misguided immune surveillance?. Leukemia Research 2004, 28:1123-1124.
25. Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000, 14:2-8.
26. Biesma D.H., van den Tweel J.G., Verdonck L.F. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997, 79:1548-1551.
27. Matsutani T., Yoshioka T., Tsuruta Y., Shimamoto T., Ohyashiki J.H., Suzuki R., Ohyashiki K. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leukemia Research 2003, 27:305-312.
28. Hamblin T.J. Immunological abnormalities in myelodysplastic syndromes. Seminars in Hematology 1996, 33:150-162.
29. Saunthararajah Y., Molldrem J.L., Rivera M., Williams A., Stetler-Stevenson M., Sorbara L., Young N.S., Barrett J.A. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. British Journal of Haematology 2001, 112:195-200.
30. Shimamoto T., Iguchi T., Ando K., Katagiri T., Tauchi T., Ito Y., Yaguchi M., Miyazawa K., Kimura Y., Masuda M., Mizoguchi H., Ohyashiki K. Successful treatment with cyclosporin a for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. British Journal of Haematology 2001, 114:358-361.
31. Kook H., Zeng W., Guibin C., Kirby M., Young N.S., Maciejewski J.P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Experimental Hematology 2001, 29:1270-1277.
32. Risitano A.M., Maciejewski J.P., Green S., Plasilova M., Zeng W., Young N.S. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004, 364:355-364.
33. Zeng W., Maciejewski J.P., Chen G., Young N.S. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. Journal of Clinical Investigation 2001, 108:765-773.
34. Langerak A.W., Szczepanski T., van der Burg M., Wolvers-Tettero I.L., van Dongen J.J. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997, 11:2192-2199.
35. Jonasova A., Neuwirtova R., Cermak J., Vozobulova V., Mocikova K., Siskova M., Hochova I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology 1998, 100:304-309.
36. Par G., Rukavina D., Podack E.R., Horanyi M., Szekeres-Bartho J., Hegedus G., Paal M., Szereday L., Mozsik G., Par A. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. Journal of Hepatology 2002, 37:514-522.
37. Banat G.A., Ihlow K., Usluoglu N., Hoppmann S., Hoeck M., Pralle H. Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses. British Journal of Haematology 2003, 123:819-829.
38. Hahn Y.S., Taube C., Jin N., Sharp L., Wands J.M., Aydintug M.K., Lahn M., Huber S.A., O'Brien R.L., Gelfand E.W., Born W.K. Different potentials of gamma delta T cell subsets in regulating airway responsiveness: V gamma 1+ cells, but not V gamma 4+ cells, promote airway hyperreactivity, Th2 cytokines, and airway inflammation. Journal of Immunology 2004, 172:2894-2902.
39. Kanehiro A., Lahn M., Makela M.J., Dakhama A., Fujita M., Joetham A., Mason R.J., Born W., Gelfand E.W. Tumor necrosis factor-alpha negatively regulates airway hyperresponsiveness through gamma-delta T cells. American Journal of Respiratory and Critical Care Medicine 2001, 164:2229-2238.
40. Lv L., Kerzic P., Lin G., Schnatter A.R., Bao L., Yang Y., Zou H., Fu H., Ye X., Gross S.A., Armstrong T.W., Irons R.D. The TNF-alpha 238a polymorphism is associated with susceptibility to persistent bone marrow dysplasia following chronic exposure to benzene. Leukemia Research 2007, 31:1479-1485.
41. Irons R.D., Stillman W.S., Colagiovanni D.B., Henry V.A. Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3691-3695.
42. Baines P., Mayani H., Bains M., Fisher J., Hoy T., Jacobs A. Enrichment of CD34 (My10)-positive myeloid and erythroid progenitors from human marrow and their growth in cultures supplemented with recombinant human granulocyte-macrophage colony-stimulating factor. Experimental Hematology 1988, 16:785-789.
43. Quentmeier H., Dirks W.G., Fleckenstein D., Zaborski M., Drexler H.G. Tumor necrosis factor-alpha-induced proliferation requires synthesis of granulocyte-macrophage colony-stimulating factor. Experimental Hematology 2000, 28:1008-1015.
44. Irons R.D., Stillman W.S. Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells 1993, 11:235-242.
45. Irons R.D., Stillman W.S. Impact of benzene metabolites on differentiation of bone marrow progenitor cells. Environmental Health Perspectives 1996, 104(Suppl. 6):1247-1250.
46. Zheng J.H., Pyatt D.W., Gross S.A., Le A.T., Kerzic P.J., Irons R.D. Hydroquinone modulates the GM-CSF signaling pathway in TF-1 cells. Leukemia 2004, 18:1296-1304.
47. Jordan M.B., Hildeman D., Kappler J., Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104:735-743.